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Abstract—Recent studies in mice have challenged the ability of bone marrow cells (BMCs) to differentiate into myocytes
and coronary vessels. The claim has also been made that BMCs acquire a cell phenotype different from the blood
lineages only by fusing with resident cells. Technical problems exist in the induction of myocardial infarction and the
successful injection of BMCs in the mouse heart. Similarly, the accurate analysis of the cell populations implicated in
the regeneration of the dead tissue is complex and these factors together may account for the negative findings. In this
study, we have implemented a simple protocol that can easily be reproduced and have reevaluated whether injection of
BMCs restores the infarcted myocardium in mice and whether cell fusion is involved in tissue reconstitution. For this
purpose, c-kit–positive BMCs were obtained from male transgenic mice expressing enhanced green fluorescence protein
(EGFP). EGFP and the Y-chromosome were used as markers of the progeny of the transplanted cells in the recipient
heart. By this approach, we have demonstrated that BMCs, when properly administrated in the infarcted heart, efficiently
differentiate into myocytes and coronary vessels with no detectable differentiation into hemopoietic lineages. However,
BMCs have no apparent paracrine effect on the growth behavior of the surviving myocardium. Within the infarct, in 10
days, nearly 4.5 million biochemically and morphologically differentiated myocytes together with coronary arterioles
and capillary structures were generated independently of cell fusion. In conclusion, BMCs adopt the cardiac cell lineages
and have an important therapeutic impact on ischemic heart failure. (Circ Res. 2005;96:000-000.)
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Several studies have suggested that adult bone marrowcells (BMCs) can differentiate into cell lineages distinct
from the organ in which they reside.1 The recognition that
BMCs maintain some of the growth potential of younger cells
has promoted a heated debate about stem cell plasticity and
the utilization of BMCs in the treatment of ischemic heart
failure.2 The efficacy of BMCs for myocardial regeneration
after infarction was documented 3 years ago,3 and this
protocol was rapidly applied clinically.4 Nine clinical trials
have been completed and several are ongoing and, with the
exception of one,5 all other show positive results.4,6–12
Because of the difficulty to demonstrate myocardial regener-
ation in humans in the absence of cardiac biopsies, three
possibilities have been raised in the interpretation of the
improvement of cardiac function in patients. They include the
development of coronary vessels that rescue hibernating
myocardium,11,12 de novo formation of myocytes8,10 and
vascular structures4,8,9,12 or the activation and growth of
resident progenitor cells via a paracrine effect12 mediated by
BMCs. These are important biological and clinical questions
that can be addressed experimentally to acquire a better
understanding of the relevance of this form of therapy for the
human disease. Similarly, the controversy on differentiation
of BMCs into cardiac lineages13–16 can be resolved by an
accurate and reproducible experimental design comple-
mented by an adequate methodological analysis.
In spite of the therapeutic efficacy of BMCs in heart
failure4,6 –12 and models mimicking the human dis-
ease,3,10,17–19 two studies13,14 and two commentaries15,16 have
presented and discussed negative results, criticizing the early
experimental data and clinical trials. They question the ability
of BMCs to regenerate dead myocardium and claim that the
original findings were a collection of artifacts and all clinical
trials were premature and “may have in fact place a group of
sick patients at risk.”14 Because of the impact that these
positive and negative findings have in the future treatment of
the postinfarcted heart in humans, we have implemented a
simple protocol that can easily be reproduced in laboratories
with experience in models of myocardial infarction in small
animals. Additionally, we have applied and emphasized the
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type of analysis that has to be performed to obtain reliable
information. By this approach, we have demonstrated that
BMCs differentiate into myocytes and coronary vessels
replacing the infarcted myocardium independently of cell
fusion.
Materials and Methods
An expanded Materials and Methods can be found in an online
data supplement available at http://circres.ahajournals.org.
Results
BMCs for Myocardial Repair
The bone marrow of male mice heterozygous for enhanced
green fluorescence protein (EGFP) was collected and the
cells were sorted with anti–c-kit coated immunobeads. Im-
munocytochemically (Figure 1A through 1F), sorted c-kit–
positive cells were 63% negative for a cocktail of antibodies
recognizing B and T lymphocytes (CD5, CD45R), monocytes
and granulocytes (CD11b, Gr-1), neutrophils,4–7 and erythro-
cytes (TER-119). Similarly, FACS analysis (Figure 1G)
showed that the c-kit–positive cells were 52% negative for
markers of hematopoietic cell lineages (CD3e, CD11b,
CD45R/B220, Gr-1, TER-119). Hematopoietic stem cell and
endothelial progenitor cell markers (CD34, Sca-1, flk1) were
present in 11% to 47% of the cells (Figure 1H and 1I).
Unexpectedly, EGFP was detected in 274% BMCs (Figure
1J and 1K). Thus, this enriched c-kit BMC population was
used here.
Myocardial Infarction and BMCs
BMCs were combined with rhodamine-labeled microspheres
for the identification of the injection sites. Because EGFP was
present in a small fraction of cells, male EGFP-positive
BMCs were injected in female infarcted mice so that EGFP
and the Y-chromosome were detected in the progeny of the
Figure 1. BMCs and myocardial regeneration. A through C, c-kit–positive cells (A, green) are largely negative for a cocktail of antibod-
ies of hematopoietic cell lineages (B and C, white). D through G, FACS profiles of c-kit–positive BMCs showing markers of hematopoi-
etic cell lineages (D) and antigens of endothelial progenitor cells (E through G). H and I, Detection of EGFP in c-kit–positive cells by
immunocytochemistry (H, green) and FACS (I). Bars10 m.
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BMCs in vivo. Two injections of 5104 BMCs each mixed with
rhodamine particles were made in proximity of the border zone
(Figure 2A through 2F). We knew that the procedure was
difficult with an inherent variability in infarct size and a 50%
probability3 of correct injection. The mouse heart beats 600
times per minute and has a left ventricular (LV) wall that is less
than 1 mm thick. These factors make the injection of cells within
the LV wall highly problematic. Thus, the unsuccessfully in-
jected mice (no rhodamine particles) were considered the most
appropriate control animals for the successfully treated mice.
5-Bromodeoxyuridine (BrdUrd) was given daily for the recog-
nition of newly formed cells with time.
Thirty-seven infarcted mice were obtained, and 18 of these
mice were studied at 5 days and 19 at 10 days after surgery.
Rhodamine particles were found in 9 and 11 mice at 5 and 10
days, respectively. Thus, a 54% rate of proper injection was
accomplished. Infarct size varied from 15% to 60% in both
groups of mice (see online data supplement). Therefore,
without an appropriate protocol it is impossible to predict the
successful or unsuccessful treatment of animals and the actual
size of the infarct in each mouse.
Myocardial Regeneration and BMCs
Myocardial regeneration was found in each of the 20
infarcted-treated mice showing rhodamine particles (Figure
2G through 2J). Conversely, myocardial regeneration was not
found in the 17 infarcted mice with unsuccessful administra-
tion of BMCs as documented by the absence of rhodamine
particles. In these cases, the lost myocardium was replaced by
collagen (Figure 2K) and there were no EGFP or
Y-chromosome labeled cells. This was in sharp contrast to
treated infarcts in which the quantity of collagen was minimal
and the cells contained in the regenerated myocardium
expressed in 20% to 25% of the cases EGFP and in 60%
to 80% of the cases carried the Y-chromosome (Figure 2L
through 2O). EGFP-Y chromosome–positive cells within the
infarct were all CD45 negative, indicating that there was no
commitment to the hematopoietic lineages (see online data
supplement). However, in nontreated infarcts, numerous
CD45-positive cells were detected at 5 and significantly less
at 10 days (see online data supplement). CD45-positive cells
were EGFP and Y-chromosome negative. Thus, consistent
with previous results,3,20 tissue regeneration with BMCs
attenuates inflammation and myocardial scarring.
In all cases, the regenerated myocardium contained new
myocytes that expressed GATA-4, Nkx2.5, MEF2C,
-sarcomeric actin, cardiac myosin heavy chain, troponin I,
and desmin. Connexin 43 and N-cadherin were detected at 5
days but were more apparent at 10 days (Figure 3A through
3J). Fibroblasts were identified between developing myocytes
(see online data supplement). Because BrdUrd was injected
daily, most of the new myocytes were labeled by BrdUrd
confirming their formation after the injection of BMCs
(Figure 4A). Two markers of cell proliferation, Ki673,19,21 and
MCM5,22 were used at euthanasia to evaluate cell growth at
5 and 10 days after BMC implantation. A significant fraction
of cycling cells was found at both intervals with both markers
(Figure 4B and 4C). The presence of EGFP and/or the
Y-chromosome offered the unequivocal documentation of the
origin of these myocytes from the BMCs. The new myocytes
were predominantly mononucleated with a small fraction
binucleated (Figure 4D). Conversely, differentiated mouse
myocytes are 94% binucleated and 5% mononucleated.23
Thus, these results exclude the contribution of preexisting
myocytes to the generation of new myocytes. The volume of
new myocytes was 350 and 600 m3 at 5 and 10 days,
respectively. Together, 2.5 and 4 million myocytes were
formed within the infarct at 5 and 10 days, respectively
(Figure 4E). New myocytes were 1/40 of spared myocytes:
23 000 to 25 000 m3. In fact, surviving myocytes showed a
16% and 25% hypertrophy at 5 and 10 days after infarction,
respectively (Figure 4F). As a result of myocyte formation,
infarct size was reduced by 6% at 5 and by 17% at 10 days
(Figure 4G and 4H).
The repair of the infarct involved the formation of arte-
rioles and capillaries (Figure 4I through 4N). At 10 days,
there were 139 mm of arterioles and 9831 mm of
capillaries per mm3 of new myocardium. For comparison,
there are 10 arterioles and 3500 capillaries per mm2 of
tissue in the adult heart. Thus, the size of myocytes and the
characteristics of the coronary vasculature were consistent
with a rather immature phenotype of the regenerated myo-
cardium. In the spared myocardium of treated hearts, only
two EGFP-positive vascular cells were found. At most, only
a few vessels were formed by BMCs in the noninfarcted
myocardium. Therefore, BMCs appear to acquire the cardiac
cell phenotype repairing the infarcted heart.
Cell Fusion and Myocardial Regeneration
Myocardial regeneration could be the result of fusion of the injected
BMCs with existing cells and formation of hybrid cells, the
consequence of BMC differentiation and cardiac lineage commit-
ment, or both. Because male BMCs were injected in female
infarcted mice, the X- and Y-chromosomes were measured to
evaluate whether cell fusion was implicated in de novo myocardial
growth. Additionally, DNA content/nucleus was determined.21
Newly formed myocytes and vascular cells had only one set of X-
and Y-chromosomes, whereas two X-chromosomes were detected
exclusively in the surviving myocytes (Figure 5A through 5L).
There were no cells in the area of cardiac repair that showed
Y-chromosome labeling in combination with more than one
X-chromosome signal. Also newly formed binucleated myocytes
carried only one Y- and one X-chromosome in each nucleus (Figure
5G and 5H). Thus, the regenerated myocytes were of male origin,
whereas the spared myocytes retained their female phenotype.
Finally, a 2C DNA content was found in each nucleus of noncyc-
ling myocytes (see online data supplement) further minimizing the
role of cell fusion in myocardial repair.
Myocyte and Vessel Growth in the
Surviving Myocardium
To determine whether the injection of BMCs had a paracrine
effect on the spared myocardium, BrdUrd-labeled myocytes
were measured in the border and distant region of treated and
untreated infarcted hearts. Additionally, the fraction of Ki67-
positive myocytes was determined to evaluate the degree of
cell replication at death. In both regions, the percentage of
BrdUrd- and Ki67-positive myocytes was comparable be-
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Figure 2. Myocardial regeneration. A through F, Anatomical images of the heart. Three infarcts are shown (A through C) together with the
localization of rhodamine particles (RPs) in A and B (red, arrowheads) and their absence in C. D through F, Injection of RPs and by inference
of BMCs in the border zone (D and E, arrowheads). Unsuccessful injection (F). G through J, Transverse section of a treated infarct (MI,
arrows) at 10 days. RPs in the border zone (circles) are shown at higher magnification (H and I, white dots). New myocytes within the infarct
are identified by -sarcomeric actin (red); the area in the rectangle is illustrated at higher magnification (J). Regenerated myocytes express, at
times, EGFP (yellow-green). K, Collagen type I and III (yellow) in an untreated-infarct. The area in the rectangle is also shown in the inset.
Asterisks indicate spared myocytes. L through O, New myocytes in treated-infarcts at 5 (L and M) and 10 (N and O) days express cardiac
myosin (red), EGFP (yellow-green), or Y-chromosome (N and O, white nuclear dots) and EGFP. Sarcomere striation in developing myocytes
at 10 days (N and O, arrows). G, Bar1 mm. H through K, Bars100 m. L through O, Bars10 m.
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tween treated and nontreated infarcted mice (Figure 6A and
6B). Also, capillary length density was similar in treated and
untreated mice (Figure 6C). These data are not consistent
with a paracrine effect of BMCs on myocytes and vessels of
the noninfarcted portion of the heart.
Ventricular Function
Myocardial regeneration did not ameliorate LV end-diastolic pres-
sure, developed pressure and anddP/dt at 5 days. However, at
10 days, these hemodynamic parameters were improved in treated-
infarcted mice (Figure 6D). These positive effects on LV perfor-
mance were not observed in untreated-infarcted mice. The improve-
ment in cardiac function with BMCs can only be accounted for by
the regeneration of myocardial mass and reduction of infarct size.
Whether few or numerous vessels are formed within the infarct, the
contractile behavior of this region does not change. Vessels do not
contract or generate force; force is developed by myocytes. It is
erroneous15 to assume that regeneration of vessels only can restore
contractile activity in the infarcted myocardium.
Figure 3. BMCs adopt the cardiomyocyte fate. A through J, Regenerating myocytes at 5 (A and B) and 10 (C through J) days express
in nuclei GATA-4 (A and B, white), Nkx2.5 (C and D, bright blue), and MEF2C (E and F, yellow) and in the cytoplasm -sarcomeric actin
(A, B, G through J, red), cardiac myosin (C and D, red) and troponin I (E and F, red). Connexin 43 between developing myocytes is visi-
ble in the insets (G and H; white, arrowheads). N-cadherin is also visible in the insets (I and J; white, arrowheads). Bars10 m.
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Immunocytochemistry and Autofluorescence
The ability of BMCs to commit to the myocyte lineage has
been challenged by negative results13,14 and observations
suggesting that the identification of GFP in skeletal myofi-
bers is the consequence of autofluorescence.24 The study
performed in Goodell’s laboratory24 erroneously implies that
native GFP fluorescence present in frozen sections of skeletal
myofibers can be confused with autofluorescence. This has
nothing to do with the detection of the overexpression of
EGFP in cardiomyocytes by immunolabeling with specific
Figure 4. Regeneration of myocytes and vessels. A through D, *Significant vs 5 days. E, Volume distribution of regenerated myocytes
at 5 (n562) and 10 (n620) days. F, Hypertrophy of spared myocytes in untreated-infarcts (U-MI) and treated-infarcts (T-MI). *Signifi-
cant vs SO. G and H, Aggregate volumes of tissue components in the new myocardium (G); reduction of infarct size by tissue regener-
ation (H). The size of the infarct, 31% in U-MI and 33% in T-MI, allowed us to compute the volume of myocardium remaining (R) and
lost (L) in the two groups of infarcted mice. The volume of new myocardium (F, solid segments) increased the volume of remaining
myocardium (RF) and decreased the volume of lost myocardium (L minus F) by the same amount. In treated-mice, infarct size was
reduced by 6% at 5 days and by 17% at 10 days. *Significant vs SO. I through N, EGFP-positive cells (I, K, L, and N, green) in the
regenerated myocardium express in nuclei the endothelial cell transcription factor Ets-1 (J and K, yellow) and the smooth muscle cell
transcription factor GATA-6 (M and N, white), and in the cytoplasm von Willebrand factor (J and K, red) and -smooth muscle actin (M
and N, red). Capillaries, arrowheads. Bars10 m.
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Figure 5. Newly formed myocytes have one set of X- and Y-chromosomes. A through L, Regenerated myocytes (A through J) have in
their nuclei one Y-chromosome (white) and one X-chromosome (magenta). Regenerated binucleated myocytes show in each nucleus
only one set of X- and Y-chromosome (G and H). Spared myocytes (K and L) have nuclei each with two X-chromosomes (magenta).
EGFP, yellow-green; -sarcomeric actin, red; nuclei, blue (PI). Bars10 m.
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anti-GFP antibody performed in this study and previously.3,21
It is difficult to understand why this unusual protocol was
used24 because immunostaining is the standard procedure
today. The advantage of the use of the antibody is apparent in
the amplification of the signal associated with the expression
of the transgene (Figure 7A through 7D). By this approach,
the signal-to-background ratio increases dramatically, 300-
fold. To confirm the presence of EGFP in the regenerated
myocardium, thick sections of the paraffin-embedded tissue
that corresponded to the areas of newly formed myocytes and
coronary vessels were used for the detection of the EGFP
transgene by PCR. A distinct band reflecting the amplified
EGFP-DNA sequence was identified (Figure 7E).
It is common practice to stain samples in the presence of a
well-established positive and negative control. Moreover, the
level of autofluorescence of the formalin-fixed, paraffin-
embedded and cut tissue section is always determined and
compared with the intensity of the fluorescence signal of the
labeled epitope. Also, the background fluorescence generated
by staining sections with the secondary antibody only is
determined. Our working policy is that the fluorescence
signal generated by immunostaining of a structure has to be at
least 30-fold higher than that accounted for by background
autofluorescence together with secondary antibody unspecific
staining (Figure 7F through 7K). Therefore, autofluorescence
is not a relevant factor when an adequate protocol of tissue
labeling and detection is used.
Discussion
BMCs Mediate Myocardial Regeneration
In the current study, we document that BMCs differentiate
into cardiac cell lineages, reconstitute the dead myocardium
after infarction, and improve ventricular function. These
positive results appear to occur independently from a para-
crine effect of BMCs on the surviving myocardium. Our
findings argue strongly in favor of differentiation of the injected
cells into the myogenic and vascular lineages as the mechanism
of cardiac repair and against cell fusion as the cause of the new
cardiac phenotype. The formed cardiac cells in the female
infarcted hearts have a male phenotype as the injected BMCs.
Cell fusion remains essentially an in vitro phenomenon with few
implications in vivo.25 Cell fusion in vivo in different organs
including the skin, the lung, the brain, and the heart is restricted
at most to a few cells which, by inference, have no physiological
consequences on baseline function or on tissue repair in patho-
logical states.25 Studies of cell fusion in the liver and skeletal
muscle are problematic because cell fusion is an inherent aspect
of the growth pathway of hepatocytes and myofibers. Under
normal physiological turnover, fusion of BMCs with parenchy-
mal cells is an extremely rare event in these tissues.25
Figure 6. Reactive growth in the surviving myocardium. A and B, Accumulation of BrdUrd-positive myocytes (A) and fraction of cycling
Ki67-positive myocytes (B) at 10 days. C, Capillary length in the border zone (BZ) and remote (REM) myocardium at 10 days. D, Func-
tional properties in SO, untreated-infarcts (U-MI), and treated-infarcts (T-MI) at 5 and 10 days. Significant vs SO* and U-MI**.
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There are several other factors that support BMC transdiffer-
entiation rather than cell fusion in myocardial regeneration after
infarction. After permanent coronary occlusion, all cells in the
supplied myocardium die in less than 5 hours. Essentially, there
are no partner cells left for fusion. Adult myocytes have a
volume of 20 000 m3 and if cell fusion occurred in our
conditions, new myocytes should have a volume of at least
20 000 m3 or larger. In contrast, these myocytes have a
maximum size of 2000 m3 and a minimum size of
100 m3. Donor-derived cells divide rapidly and extensively,
whereas tetraploid cells divide slowly and might not divide at all
if one of the partners is a terminally differentiated myocyte.19
Fusion of a BMC to a myocyte that has reached irreversible
growth arrest cannot stimulate its reentry into the cell cycle.26
Figure 7. EGFP immunolabeling and detection of the transgene. A through D, The same field of regenerated myocardium is shown
without immunostaining (A). Fluorescence signal is the combination of the native EGFP fluorescence (green) and the autofluorescence
associated with formalin fixation. Green signal enhanced by 30-fold is shown for the same field in B. In both cases, the EGFP-positive
cells are barely detectable. C, When the anti-EGFP antibody is applied the fluorescence signal for the myocytes expressing EGFP is
increased 400-fold with respect to A. Labeling of myocytes for cardiac myosin is documented in D (red). E, EGFP band is evident in
the DNA collected from samples of regenerated myocardium in treated hearts (T). Cells obtained from EGFP transgenic mice were
used as a positive control () and myocardium obtained from untreated-mice (U) was used as negative control. F through I, Levels of
fluorescence signal in the same field of regenerated myocardium under four different conditions. F illustrates the degree of autofluores-
cence of the section before immunostaining. G, Enhancement of the autofluorescence signal by 50-fold. Fluorescence of H reflects the
nonspecific binding of the secondary antibody in the absence of labeling with the primary antibody. I, Intensity of fluorescence signals
after labeling with antibodies specific for -sarcomeric actin (red) and EGFP (green) and the subsequent staining with the appropriate
secondary antibodies. The Y-chromosome was detected by FISH (white nuclear dots). The real signals are at least 100-fold stronger
than the baseline autofluorescence. Bars10 m.
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Cell fusion should generate binucleated myocytes, with one
tetraploid and one diploid nucleus, or myocytes with three
diploid nuclei. This was not the case.
The cre-lox genetic system is frequently used to detect cell
fusion. However, this system is not perfect. It is surprising that
the possibility of metabolic cooperation27 was not considered
because this phenomenon may account for some of these
observations. By metabolic cooperation, a cell acquires the
cre-recombinase from a neighboring cell and undergoes excision
of the flox-flanked DNA segment in the absence of cell fusion.
The exchange of the enzyme between the donor cell and the
recipient cell occurs through intercellular junctions. Metabolic
cooperation is important in a tissue that is functionally a
syncytium. Theoretically, Y-chromosome-EGFP–positive myo-
cytes could have resulted from hybrid cells that underwent
reductive cell division converting the hyperploid cell to a diploid
karyotype, which concealed their fusion history.2 Reductive cell
division of hybrid cells in vivo has only been documented in
hepatocytes generated under a stringent selection pressure that
conferred them survival and growth advantage.28 These
“pseudodiploid” cells accumulate slowly and are found together
with a large number of fused cells.25 Conversely, we found the
2.5 to 4 million donor-derived myocytes to be diploid with an
XY-chromosome complement as early as 5 and 10 days after
cell implantation. The short interval between the injection of
BMCs and the generation of diploid male cells makes reductive
mitosis an unlikely possibility.
Controversy on BMC Transdifferentiation
The current results are consistent with previous observations
made in our laboratory3,19,20 in which an enriched population of
c-kit–positive BMCs regenerated the infarcted myocardium.
Similarly, BMCs and endothelial progenitor cells improve car-
diac function in humans.4,6–12 So far, only one negative study
has been reported.5 Moreover, a variety of bone marrow–
derived cells capable of differentiating into the cardiac myogenic
lineage have been described.3,10,17,18,20,29,30 It is therefore, diffi-
cult to reconcile our findings and the clinical and experimental
studies with the claim made recently.13,14 The most likely
possibility is a technical difference in the experimental protocol,
identity of the therapeutic cell(s), tissue preparation, and immu-
nocytochemical analysis of the myocardium.
The utilization of frozen tissue samples13,14 has severe limi-
tations in terms of the quality of the sections, immunolabeling,
and microscopic resolution. The infarct is rarely preserved in
frozen sections. Similarly, the 100% degree of success in the
injection of cells in the mouse heart14 has no precedent and will
never be matched. Moreover, the lack of changes in LVEDP and
an 8% mortality with infarcts of 60% is astonishing.14 This
unusual result has been attributed to a better postoperative care
of the animals. Infarct size is a critical determinant of survival in
animals and humans. In spite of the perfect care that patients
have in the most sophisticated medical centers, a 46% infarct
results in intractable heart failure. Rodents are not different
although they can survive slightly larger infarcts.31 The hearts
analyzed immunocytochemically for the presence of cardiac
regeneration were not the same studied functionally or with
routine histology.13,14 Thus, whether coronary ligation was
unsuccessful or a small or large infarct was obtained was not
determined. This is critical because of the complexity of the
model and the difficulty of producing an infarct and a correct
injection of cells. Most importantly, as shown here, the size of
new myocytes averages 500 m3 and cells of this volume would
not be recognized by the approach and methodology used in
these studies.13,14 This is apparent in the micrographs that
illustrate clusters of EGFP-positive cells; the EGFP signal is
diffuse to the cell cytoplasm and can easily obfuscate a thin rim
of myocyte specific proteins. Double labeling for the EGFP-
transgene and myocyte cytoplasmic proteins was never per-
formed on the same section13 and negative claims were based on
only two animals that were supposedly properly infarcted and
injected with cells comparable to those used in our early study.3
The improvement in ventricular function claimed in chronically
treated animals in the absence of myocardial regeneration is
based on unusual echocardiographic data that are not supported
by hemodynamic measurements.14
The same limitations can be found in another study in which
engraftment of BMCs was observed within the infarct but
myocyte formation was considered modest and restricted to the
surviving myocardium.32 In fact, myocyte regeneration in the
infarcted region seems to be present in some of the illustrations
although the colocalization of -Gal and GFP indicative of cell
fusion was never determined in the same sections. Histochem-
istry was used to detect -Gal, and immunolabeling was used for
the identification of GFP. Moreover, the utilization of frozen
sections precludes the subsequent recognition of small cells of
the size of newly formed myocytes. Also, the diffuse localization
of CD45 to the cell cytoplasm further questions some of the
technical aspects of this report.
Intrinsic genetic markers have been proposed as the today
gold standard for these types of studies.13–16 We believe that the
detection of the Y chromosome in newly generated myocytes
implemented in the early report3 and used in this study falls well
within this category. Most importantly, any genetic marker
requires its subsequent identification by histochemical13 or
immunocytochemical14 procedures. If limitations exist in these
protocols, the powerful genetic markers lead to false collection
of data and erroneous interpretations and conclusions. The
assumption made by Balsam et al14 and Murry at al13 that the
technical approach that they have used in the identification and
measurement of myocardial structures is superior to that used in
our laboratory does not reflect any scientific reality but the
emotional disbelief that BMCs can adopt myocardial cell lin-
eages and repair the injured heart. It is unfortunate that two
editorials15,16 accompanying the publication of these studies
further promoted this negative view.
The esoteric nonphysiological models of parabiosis with
complete blood chimerism14 or with reconstituted EGFP-
positive bone marrow13 were introduced to question the
ability of BMCs to acquire a cardiomyocyte lineage. Surpris-
ingly, the negative results were considered of great relevance
for the understanding of BMC transdifferentiation. The lim-
itation of the therapeutic potential of circulating BMCs is not
new. Therefore, the paradigm offered in these studies13–16
defeats any clinical reality and the dramatic problem of
ischemic heart failure. If circulating BMCs would have the
ability to spontaneously repair damaged organs, infarcts of the
heart, brain, skin, kidney, and intestine would be easily recon-
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stituted and the majority of current human diseases would not
exist. These models are of little value to resolve the controversy
at hand and can only add confusion to the confusion. The issue
in need of resolution is whether BMCs injected directly in the
infarct or in the border zone differentiate into the cardiac cell
lineages and contribute to myocardial regeneration.
Over the past 2 years, most of the results claiming hemato-
poietic stem cell (HSC) plasticity have been questioned2 because
of imprecise identification of the administered cells, incomplete
characterization of their differentiated progeny, and/or the for-
mation of hybrid cells by fusion of the donor to the differentiated
recipient cells. At the same time, there have been an increasing
number of detailed reports documenting the existence of multi-
potent cells in the bone marrow and, among them, cells able to
differentiate into the cardiac myocyte lineage.20 Why myocardial
regeneration from BMCs has been caught in the HSC contro-
versy remains unexplained.
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